Cargando…
Past, Current, and Future of Immunotherapies for Prostate Cancer
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate canc...
Autores principales: | Boettcher, Adeline N., Usman, Ahmed, Morgans, Alicia, VanderWeele, David J., Sosman, Jeffrey, Wu, Jennifer D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749031/ https://www.ncbi.nlm.nih.gov/pubmed/31572678 http://dx.doi.org/10.3389/fonc.2019.00884 |
Ejemplares similares
-
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015) -
Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
por: Fenton, Sarah E., et al.
Publicado: (2023) -
Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy
por: Baker, Abu, et al.
Publicado: (2023) -
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
por: Punekar, Salman R., et al.
Publicado: (2022) -
Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives
por: Su, Zhi Yi, et al.
Publicado: (2022)